

Marsh & McLennan (MMC)

\$104.30 (As of 05/12/20)

Price Target (6-12 Months): **\$110.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 04/01/19)

Prior Recommendation: Outperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM:F

Value: F

Growth: F

Momentum: D

Summary

Marsh & McLennan's first-quarter 2020 earnings per share of \$1.64 surpassed the Zacks Consensus Estimate by 5.1% and also rose 8% year over year on the back of solid revenues. Its shares have outperformed its industry in a year's time. The company is well-poised to grow on significant investments and acquisitions made within its operating units, launch of new products, enhancements to digital capabilities and branching out into new businesses. Its revenues have been increasing over the past many years. However, it has been suffering a low investment income phase. Its rising operating expenses and high debt level continue to bother. It has also been witnessing a rise in its long-term leverage ratio, which raises risk for Marsh & McLennan. High exposure to adverse forex is another headwind for Marsh & McLennan.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$119.88 - \$74.34
20 Day Average Volume (sh)	2,221,090
Market Cap	\$52.8 B
YTD Price Change	-6.4%
Beta	0.88
Dividend / Div Yld	\$1.82 / 1.7%
Industry	Insurance - Brokerage
Zacks Industry Rank	Top 25% (63 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	5.1%
Last Sales Surprise	-0.0%
EPS F1 Est- 4 week change	-8.5%
Expected Report Date	08/04/2020
Earnings ESP	0.0%
P/E TTM	21.8
P/E F1	22.6
PEG F1	1.9
P/S TTM	3.1

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	4,806 E	4,366 E	4,015 E	4,443 E	17,514 E
2020	4,651 A	4,157 E	3,787 E	4,189 E	16,795 E
2019	4,071 A	4,349 A	3,968 A	4,264 A	16,652 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$1.71 E	\$1.29 E	\$0.81 E	\$1.29 E	\$5.06 E
2020	\$1.64 A	\$1.14 E	\$0.70 E	\$1.15 E	\$4.62 E
2019	\$1.52 A	\$1.18 A	\$0.77 A	\$1.19 A	\$4.66 A

*Quarterly figures may not add up to annual.



The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 05/12/2020. The reports text is as of 05/13/2020.

Overview

Founded in 1871 and based in New York, Marsh & McLennan Companies Inc. is a globally leading insurance broker. Currently operating under the Marsh and Guy Carpenter brands, the company is a global professional services firm providing risk and insurance services, risk consulting, and employee benefits consulting services to clients worldwide.

Marsh & McLennan provides insurance and consulting services through approximately 55,000 employees worldwide to clients in more than 130 countries. Geographically, 55% of Marsh & McLennan's revenues were generated from outside the U.S. while the remaining 45% was earned in the U.S. The company conducts business primarily through:

- **Risk and Insurance Services (Accounted for 57.6% of revenues in 2019):** This segment is operated through Marsh and Guy Carpenter. Marsh is world leader in insurance brokering, providing risk management, insurance and reinsurance broking and insurance program management services across public and private entities.
- **Consulting (42.4%):** This segment comprises Mercer and Oliver Wyman Group. Mercer is a leading global provider of consulting, outsourcing and investment services. Oliver Wyman Group delivers advisory services to clients through three operating units, each of which is a leader in its field. Lippincott helps clients create, develop and manage their corporate branding, identity and image. NERA Economic Consulting advises corporations, law firms and government entities on the economics of competition, regulation, public policy, finance and litigation.



Reasons To Buy:

- ▲ **Growing Top Line:** Marsh & McLennan's operating performance has been favorable for the past many years, driven by its diverse product offerings, a wide geographic footprint and strong client retention. Its revenues have been increasing consistently since 2010 (except in 2015, which saw a revenue dip by just 0.4%). This trend continued in 2019 with the metric rising 11% year over year. This significant uptick also marks the highest annual revenue growth rate for the company in 20 years. In the first quarter of 2020, its revenues of \$4.7 billion were up 5% on an underlying basis owing to strong Risk and Insurance Services plus Consulting Segments. Although revenues might remain suppressed this year due to the impact of COVID-19 pandemic, we are hopeful about the company's bottom line, which might bounce back on the back of acquisitions made over the past many years, significant capital expenditures undertaken for growth, launch of new product and services, enhancements to digital capabilities and branching out into new businesses.
- ▲ **Inorganic Growth:** Acquisitions form one of the core growth strategies at Marsh and McLennan. The company has made numerous purchases within its different operating units that have enabled it to enter new geographical regions, expand within the existing ones, foray into new businesses, develop new segments and specialize within its existing businesses. The company's acquisition of JLT in 2019 has expanded its capabilities going forward. It is on track to achieve its \$350 million of JLT savings by the end of 2021. The Risk and Insurance Services segment completed two acquisitions in the first quarter. Constant buyouts made by company poise it well for long-term growth.
- ▲ **Capital Deployment:** The company has maintained a strong balance sheet and financial flexibility, including consistent cash flow generation, for the past many years. Its disciplined capital management through share buyback and dividend payments has cemented investors' confidence in the stock. In May 2019, its board of directors hiked its quarterly cash dividend by 10%. Its current dividend yield of 1.8% is higher than the industry average of 1.5%. Although it doesn't expect to buy back shares for 2020, we remain hopeful that the same will resume once the pandemic effect ends.
- ▲ **Strong ROE:** Further, Marsh & McLennan's trailing 12-month return on equity (ROE) reinforces its growth potential. The company's 30.9% ROE better its industry average of 27.7%, reflecting its efficiency in utilizing the shareholders' funds.
- ▲ **Share Price Impact:** In a year's time, shares of the company have outperformed its industry. Its solid fundamentals such as an improving top line and a sturdy balance sheet should continue driving the stock going forward.

Strategic acquisitions, growing revenues on the back of diverse product offerings and capital deployment should drive long-term growth for the company.

Reasons To Sell:

- ▼ **Low Investment Income:** The company now has a much smaller private equity portfolio and its investment income has been deteriorating over the past few years. In 2018, the company incurred a net investment loss of \$12 million against its net investment income of \$15 million in 2017. The company reported a net investment loss of \$2 million in the first quarter of 2020 versus the net investment income of \$5 million in the first quarter of 2019. Moreover, the low interest rate environment might keep the investment income under pressure.
- ▼ **Escalating Expenses:** The company's operating expenses escalated over the last several years due to higher compensation and benefits. The same further increased 14.7% and 14.3% in 2019 and the first quarter of 2020, respectively, due to higher compensation and benefits as well as other operating costs. A persistent escalation of expenses might weigh on the company's margins.
- ▼ **Forex Volatility:** Due to its presence in more than 130 countries, the company is exposed to foreign exchange volatility. Notably, the company is susceptible to the U.S. hurricane season. Management expects an adverse forex to induce a headwind of 86 cents per share for the remaining year.
- ▼ **Weak 2020 Guidance:** The company withdrew its initial guidance for 2020 due to the current environment of uncertainties. For now, it expects a decline in the underlying revenues due to the coronavirus outbreak. The company expects Guy Carpenter to witness a strong first half but a soft second half in 2020. It also anticipates Mercer to witness a fall in its underlying revenues. Moreover, management expects Oliver Wyman to see dented underlying revenues in the second and third quarter.
- ▼ **Unfavorable Capital Position:** The company saw its long-term debt level increase from \$2.6 billion to \$10.7 billion during the 2013-2019 period. Total debt of the company accounts for 60.1% (compared with 57.5% as of Dec 31, 2019) of its capital, higher than the industry average of 52.9%. Its times interest earned now stands at 5.7X (in-line sequentially), lower than its industry average of 6.1X. As of Mar 31, 2020, the company had cash and cash equivalents worth \$1.5 billion and a \$1.8-billion credit facility of which \$800 million remained unused at the end of the first quarter. It even added a new \$1-billion line of credit to its borrowing capacity. However, total available cash and credit facilities are lower than its total debt load of \$11.2 billion. The company's next debt maturities are in December 2020 and January 2021. Thus, its lack of financial flexibility is a cause for concern.

Low investment income and increasing expenses due to higher compensation and benefits should weigh on overall earnings. Its high debt level also bothers.

Last Earnings Report

Marsh & McLennan's Q1 Earnings Beat, Rise Y/Y

Marsh & McLennan delivered first-quarter 2020 adjusted earnings per share of \$1.64, surpassing the Zacks Consensus Estimate by 5.1% on the back of solid revenues. Moreover, the same increased 8% year over year.

Marsh & McLennan's consolidated revenues of \$4.7 billion were up 5% on an underlying basis. This upside is majorly attributable to the Risk and Insurance Services plus Consulting Segments. The top line missed the Zacks Consensus Estimate by 0.1%.

Total operating expenses of \$3.6 billion in the first quarter were up 14.3% year over year due to higher compensation and benefits as well as other operating expenses.

Quarterly Segmental Results

Risk and Insurance Services

Revenues at the Risk and Insurance Services segment were \$2.9 billion, up 5% on an underlying basis. Adjusted operating income rose 20% to \$932 million from the prior-year quarter's level.

Marsh, a unit within this segment, generated revenues of \$2.1 billion, up 5% on an underlying basis. In U.S./Canada, underlying revenues rose 5% year over year.

Underlying revenue growth from international operations of 4% includes 6% increase of the metric in the Asia Pacific, 4% in EMEA and a 3% rise in Latin America.

Another unit under this segment, Guy Carpenter, displayed 7% revenue growth on an underlying basis in the quarter under review.

Consulting

The Consulting segment's revenues inched up 3% on an underlying basis to \$1.8 billion. Also, adjusted operating income dipped 1% to \$289 million.

A unit within this segment, Mercer, generated revenues of \$1.3 billion, up 5% on an underlying basis. Wealth's revenues were up 3% on an underlying basis. Health and Career's revenues were each up 8% and 2% year over year on an underlying basis.

Another unit, Oliver Wyman Group, registered revenues of \$511 million, flat year over year on an underlying basis.

Business Update

The company repaid \$500 million of senior notes in the first quarter.

Financial Update

Marsh & McLennan exited the first quarter of 2020 with cash and cash equivalents of \$1.5 billion, up 28.1% from the level at 2019 end. Net cash used in operating activities totaled \$638 million, up 131.2% year over year.

As of Mar 31, 2020, Marsh & McLennan's total assets were \$31.3 billion, up 0.1% from the figure as of Dec 31, 2019. Total equity was \$7.5 billion, down 6.2% from the level at 2019 end.

Quarter Ending 03/2020

Report Date	Apr 30, 2020
Sales Surprise	-0.04%
EPS Surprise	5.13%
Quarterly EPS	1.64
Annual EPS (TTM)	4.78

Recent News

Marsh & McLennan's Unit Acquires Assurance to Boost Portfolio — Apr 2, 2020

Marsh & McLennan Companies, Inc.'s unit Marsh has acquired Assurance Holdings, Inc., one of the leading independent agencies in the United States. The buyout was mainly executed by the middle market agency unit of Marsh known as the Marsh & McLennan Agency LLC (MMA). The combination of the companies is expected to generate better results.

Marsh & McLennan Arm Acquires Ironwood Insurance — Jan 16, 2020

Marsh & McLennan's subsidiary Marsh has acquired Ironwood Insurance Services, LLC, one of the leading independent brokers in the Southeast. The buyout was mainly executed by the middle market agency unit of Marsh, known as the Marsh & McLennan Agency LLC. However, further terms of the deal were kept under wraps.

Marsh & McLennan Declares Quarterly Cash Dividend — Jan 15, 2020

Marsh & McLennan has announced a quarterly dividend of 45.5 cents per share, payable Feb 14, 2020 to its stockholders of record on Jan 29, 2020.

Mercer Global Assets Reach OCIO Industry Milestone — Dec 17, 2019

Mercer has announced that its global assets under management achieved a new milestone of \$304.5 billion as of Nov 30, 2019.

Valuation

Marsh & McLennan's shares are 6.4% and up 9.9% in the year-to-date period and over the trailing 12-month period, respectively. Stocks in the Zacks sub-industry and the Zacks Finance sector are down 8.4% and 26.4% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry and sector are up 5.2% and down 20%, respectively.

The S&P 500 index is down 9% in the year-to-date period and up 3.1% in the past year.

The stock is currently trading at 21.83x forward 12-month earnings, which compares to 19x for the Zacks sub-industry, 14.8x for the Zacks sector and 21.13x for the S&P 500 index.

Over the past five years, the stock has traded as high as 24.11x and as low as 14.74x, with a 5-year median of 18.69x. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$110 price target reflects 23.06x forward 12-month earnings.

The table below shows summary valuation data for MMC

Valuation Multiples - MMC					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	21.83	19	14.8	21.13
	5-Year High	24.11	21.01	16.18	21.13
	5-Year Low	14.74	14.5	11.58	15.18
	5-Year Median	18.69	16.67	13.95	17.45
P/S F12M	Current	3.1	3.09	5.81	3.3
	5-Year High	3.38	3.31	6.7	3.44
	5-Year Low	2	1.83	4.99	2.55
	5-Year Median	2.7	2.51	6.04	3.02
P/B TTM	Current	7.09	5.52	2.03	3.77
	5-Year High	7.59	6.85	2.9	4.55
	5-Year Low	3.98	3.33	1.71	2.85
	5-Year Median	5.6	4.58	2.51	3.64

As of 05/12/2020

Industry Analysis Zacks Industry Rank: Top 25% (63 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
eHealth Inc (EHTH)	Outperform	1
American Financial Group Inc (AFG)	Neutral	3
Arthur J GallagherCo (AJG)	Neutral	3
The Allstate Corporation (ALL)	Neutral	2
Aon plc (AON)	Neutral	3
BrownBrown Inc (BRO)	Neutral	3
Erie Indemnity Company (ERIE)	Neutral	3
Robert Half International Inc (RHI)	Underperform	4

Industry Comparison Industry: Insurance - Brokerage				Industry Peers		
	MMC	X Industry	S&P 500	AJG	AON	BRO
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	3
VGM Score	F	-	-	D	D	F
Market Cap	52.79 B	2.21 B	19.25 B	16.50 B	44.65 B	10.63 B
# of Analysts	9	6	14	7	8	5
Dividend Yield	1.75%	1.13%	2.21%	2.07%	0.91%	0.91%
Value Score	F	-	-	D	D	D
Cash/Price	0.03	0.09	0.06	0.16	0.02	0.07
EV/EBITDA	17.32	14.86	11.70	14.20	18.24	15.72
PEG Ratio	1.91	2.62	2.61	2.04	NA	2.62
Price/Book (P/B)	7.08	2.77	2.61	3.25	13.73	3.05
Price/Cash Flow (P/CF)	17.38	16.64	10.36	13.90	16.18	19.93
P/E (F1)	22.58	22.38	19.13	22.16	19.81	26.19
Price/Sales (P/S)	3.06	2.81	1.96	2.33	4.03	4.30
Earnings Yield	4.43%	4.47%	5.00%	4.52%	5.05%	3.81%
Debt/Equity	1.51	0.33	0.75	0.85	1.91	0.43
Cash Flow (\$/share)	6.00	2.99	7.01	6.26	11.94	1.88
Growth Score	F	-	-	C	B	D
Hist. EPS Growth (3-5 yrs)	11.97%	12.31%	10.82%	10.92%	11.29%	15.14%
Proj. EPS Growth (F1/F0)	-0.93%	2.87%	-10.31%	7.59%	6.38%	2.29%
Curr. Cash Flow Growth	11.40%	6.15%	5.83%	9.99%	-0.54%	15.55%
Hist. Cash Flow Growth (3-5 yrs)	9.25%	13.04%	8.52%	13.27%	3.75%	10.82%
Current Ratio	1.13	1.29	1.27	1.07	1.29	0.97
Debt/Capital	60.12%	24.13%	44.25%	45.98%	65.64%	29.89%
Net Margin	10.33%	9.63%	10.59%	9.63%	14.84%	17.69%
Return on Equity	30.94%	14.70%	16.33%	15.29%	63.91%	12.71%
Sales/Assets	0.55	0.35	0.55	0.36	0.38	0.33
Proj. Sales Growth (F1/F0)	0.86%	0.38%	-2.53%	-1.51%	-1.45%	3.04%
Momentum Score	D	-	-	F	D	D
Daily Price Chg	0.20%	0.00%	-2.55%	0.20%	0.63%	-1.16%
1 Week Price Chg	7.09%	5.44%	3.23%	11.47%	6.48%	7.24%
4 Week Price Chg	4.89%	2.27%	-0.84%	0.57%	-0.42%	-5.35%
12 Week Price Chg	-12.68%	-17.87%	-21.82%	-19.80%	-17.87%	-22.03%
52 Week Price Chg	9.91%	0.59%	-10.27%	5.52%	8.52%	19.61%
20 Day Average Volume	2,221,090	79,523	2,520,117	1,412,328	1,400,794	1,598,187
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	-8.46%	-5.79%	-6.29%	-4.52%	-5.90%	-6.04%
(F1) EPS Est 12 week change	-8.90%	-6.63%	-16.21%	-5.53%	-6.35%	-6.89%
(Q1) EPS Est Mthly Chg	-13.07%	-13.07%	-12.28%	-12.45%	-10.06%	-11.18%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	F
Growth Score	F
Momentum Score	D
VGM Score	F

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.